Don’t Rely on Omega-3s for Cardiovascular Benefits
January 2021
Do omega-3 fatty acid supplements reduce CV risk?
Mounting evidence suggests they don’t...despite prior evidence with Rx Vascepa (icosapent ethyl), a form of EPA (eicosapentaenoic acid).
Vascepa 2 g BID is approved to reduce CV risk in some high-risk patients with moderately elevated triglycerides despite statins.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote